Description of the medicine: Octreotide (Octreotide)
Synonym: Sandostatin, Sandostatin, Somatostatinum.
A synthetic peptide (octapeptide), which is close in structure and action to natural (endogenous) somatostatin, but differs significantly more stability and duration of action.
Subcutaneous injection of octreotide is rapidly absorbed; maximum plasma concentration is reached within 30 minutes; when administered intravenously, it is allocated in 2 phases with a half-life of 10 and 90 minutes.
Octreotide (sandostatin) is used to reduce the concentration of growth hormone with acromegaly, including in cases of insufficient effectiveness of dopamine agonists (see Bromocpiptin); to relieve symptoms associated with endocrine tumors of the gatro-entero-pancreatic system; for the prevention of complications after operations on the pancreas; with profuse secretory diarrhea and reflex diarrhea associated with AIDS, dumping syndrome, astromic pancreatitis.
Usually prescribed subcutaneously. With acromegaly, 0.05-0.1 mg (50-100 μg) is administered at intervals of 8 or 12 hours. The dose is specified on the basis of determining the concentration of growth hormone, clinical symptoms, tolerance. Typically, the optimal daily dose is 0.3 mg. The maximum oral dose is 1.5 mg.
In endocrine tumors of the gatro-entero-pancreatic system, 0.05 mg (50 μg) is administered 1-2 times a day, with a gradual increase (if necessary) up to 3 times a day.
With diarrhea, 0.1-0.2 mg is administered 2-3 times a day for 5-7 days.
With refractory diarrhea associated with AIDS, 0.1-0.2 mg 3 times a day is administered (if necessary, up to 0.3 and more mg 3 times a day).
For the prevention of complications after pancreatic surgery, administer 0.1 mg 3 times a day for 7 days, starting 1 hour before surgery.
The daily dose should not usually exceed 0.75 mg (750 mcg) for adults.
Children are administered at a rate of 0.001-0.01 mg (1-10 μg) per 1 kg of body weight.
Subcutaneous injections of the drug are painful.
In some cases, resorted to intravenous administration.
Octreotide must be used under close medical supervision with laboratory tests.
Local side effects include pain, itching, burning at the injection site.
Anorexia, nausea, vomiting, abdominal pain, diarrhea, steatorrhea can be observed.
Possible impaired glucose tolerance and liver function, the appearance of stones in the biliary tract (with prolonged use of the drug).
Sometimes pituitary tumors producing somatotropin may increase.
During pregnancy and lactation, the use of sandostatin is possible only according to absolute indications.
Release form: solution for injection in ampoules containing 0.05; 0.1 or 0.5 mg (50; 100 or 500 mcg) in 1 ml; refillable vials containing 1 mg (1000 μg) in 5 ml of solvent.
Storage: at a temperature of +2 to +8 C (up to 2 weeks at room temperature).